Overview
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Basic Stats
The share price of Veracyte, Inc. as of September 5, 2025 is $32.45 / share. This is an increase of 6.95% from the prior week. The market cap (or net worth) of Veracyte, Inc. as of September 5, 2025 is $2,543.80 MM.
The Factor Analysis chart (below right) shows a view of Veracyte, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 2,543.80 MM |
| EV | 2,324.31 MM |
| Shares Out. | 78.39 MM |
| Earnings Date | |
| EPS (TTM) | 0.34 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.36 |
| Short Shares Avail. | 0.70 MM |
| Short Interest | 8.16 MM |
| Short Float | 10.43 % |
| Days to Cover | 8.56 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 9.00 % |
| Volatility (1 yr) | 0.50 |
| Beta | 1.09 |
| Sharpe Ratio (1 yr) | 0.10 |
| Sortino Ratio (1 yr) | 0.17 |
| PE Ratio | 96.59 |
| Price/Book | 2.08 |
| Price/TBV | 7.23 |
| Book/Market | 0.48 |
| EBIT/EV | 0.01 |
| EBIT(3yr avg)/EV | -0.01 |
| ROA | 0.02 |
| ROE | 0.02 |
| ROIC | 0.02 |
| CROIC | -0.01 |
| OCROIC | 0.07 |
| Implied Volatility | 65.97 % |
| Put/Call OI Ratio | 0.20 |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Veracyte, Inc. is $42.05. The forecasts range from a low of $28.28 to a high of $55.65. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Veracyte, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-18 | Raymond James | Outperform | Market Perform | Downgrade |
| 2023-01-05 | Scotiabank | Sector Outperform | Initiate | |
| 2022-11-04 | Raymond James | Outperform | Maintains | |
| 2022-11-04 | Morgan Stanley | Underweight | Maintains | |
| 2022-11-03 | SVB Leerink | Outperform | Maintains | |
| 2022-11-03 | Needham | Buy | Maintains | |
| 2022-08-04 | Raymond James | Outperform | Maintains | |
| 2022-08-03 | Needham | Buy | Maintains | |
| 2022-05-05 | Stephens & Co. | Overweight | Maintains | |
| 2022-05-04 | Raymond James | Outperform | Maintains | |
| 2022-05-04 | Needham | Buy | Maintains | |
| 2022-05-04 | Morgan Stanley | Underweight | Maintains | |
| 2022-03-15 | Needham | Buy | Maintains | |
| 2022-03-02 | Stephens & Co. | Overweight | Maintains | |
| 2022-03-01 | SVB Leerink | Outperform | Maintains | |
| 2022-03-01 | Raymond James | Outperform | Maintains | |
| 2022-01-07 | Stephens & Co. | Overweight | Initiate | |
| 2021-11-10 | Raymond James | Outperform | Maintains | |
| 2021-07-30 | SVB Leerink | Outperform | Maintains | |
| 2021-07-30 | Needham | Buy | Maintains | |
| 2021-07-30 | Morgan Stanley | Underweight | Maintains | |
| 2021-07-14 | SVB Leerink | Outperform | Maintains | |
| 2021-06-28 | Raymond James | Outperform | Maintains | |
| 2021-06-15 | Raymond James | Outperform | Initiate | |
| 2021-05-18 | Truist Securities | Buy | Maintains | |
| 2021-05-12 | Morgan Stanley | Underweight | Maintains | |
| 2021-05-11 | SVB Leerink | Outperform | Maintains | |
| 2021-05-11 | Needham | Buy | Maintains | |
| 2021-02-22 | Morgan Stanley | Underweight | Maintains | |
| 2021-02-19 | Morgan Stanley | Underweight | Maintains | |
| 2021-02-18 | SVB Leerink | Outperform | Maintains | |
| 2021-02-08 | SVB Leerink | Outperform | Maintains | |
| 2021-01-28 | Truist Securities | Buy | Initiate | |
| 2020-11-10 | KeyBanc | Sector Weight | Initiate | |
| 2020-11-04 | BTIG | Buy | Maintains | |
| 2020-11-03 | SVB Leerink | Outperform | Maintains | |
| 2020-11-03 | Needham | Buy | Maintains | |
| 2020-09-09 | Morgan Stanley | Underweight | Initiate | |
| 2020-07-31 | SVB Leerink | Outperform | Maintains | |
| 2020-07-31 | Needham | Buy | Maintains | |
| 2020-05-07 | SVB Leerink | Outperform | Maintains | |
| 2020-02-26 | Needham | Buy | Maintains | |
| 2019-07-31 | Lake Street | Buy | Initiate | |
| 2019-07-02 | Needham | Buy | Initiate | |
| 2018-11-29 | Janney Capital | Buy | Neutral | Downgrade |
| 2017-11-07 | Leerink Swann | Outperform | Maintains | |
| 2017-11-07 | Janney Capital | Buy | Neutral | Downgrade |
| 2016-11-29 | Janney Capital | Neutral | Buy | Upgrade |
| 2015-04-06 | BTIG Research | Buy | Initiate | |
| 2014-10-07 | Stephens & Co. | Overweight | Initiate | |
| 2014-08-14 | Leerink Swann | Outperform | Maintains | |
| 2014-06-20 | PiperJaffray | Overweight | Initiate | |
| 2013-11-26 | Morgan Stanley | Overweight | Initiate | |
| 2023-02-23 | Needham | Buy | Maintains | |
| 2023-05-08 | Stephens & Co. | Overweight | Reiterate | |
| 2023-11-10 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2023-08-09 | Needham | Buy | Buy | Maintains |
| 2023-10-23 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-08-09 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2023-10-20 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-11-08 | Needham | Buy | Buy | Maintains |
| 2023-10-10 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-04-15 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-02-26 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-05-08 | Needham | Buy | Buy | Maintains |
| 2024-02-23 | Needham | Buy | Buy | Maintains |
| 2024-08-28 | Needham | Buy | Buy | Maintains |
| 2024-11-08 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-10-17 | Leerink Partners | Outperform | Outperform | Maintains |
| 2024-08-07 | Needham | Buy | Buy | Maintains |
| 2025-01-29 | Needham | Buy | Buy | Maintains |
| 2024-12-05 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2024-10-16 | UBS | Buy | Initiate | |
| 2024-11-07 | UBS | Buy | Buy | Maintains |
| 2024-11-07 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-11-07 | Needham | Buy | Buy | Maintains |
| 2024-11-18 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2025-02-25 | Guggenheim | Buy | Buy | Reiterate |
| 2025-02-25 | UBS | Buy | Buy | Maintains |
| 2025-02-25 | Needham | Buy | Buy | Reiterate |
| 2024-08-12 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2024-10-10 | Guggenheim | Buy | Initiate | |
| 2025-03-20 | Craig-Hallum | Buy | Initiate | |
| 2025-03-26 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-04-09 | Guggenheim | Buy | Buy | Maintains |
| 2025-05-08 | Needham | Buy | Buy | Maintains |
| 2025-05-08 | UBS | Buy | Buy | Maintains |
